Emerfetamab

艾迈妥单抗

Report date: 2026/03/19 16:46:26

Base Information

Drug NameEmerfetamab

Drug Alias NameAMG673AMG-673

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers

Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitorsT-cell surface glycoprotein CD3 epsilon chain modulators

TargetsMyeloid cell surface antigen CD33T-cell surface glycoprotein CD3 epsilon chain

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaGermany +[4]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines Ltd

Inactive CompaniesAmgen Inc

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A